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 The use of automation has been standardized for generations in many industries, ranging 
from car manufacturing to oil refinery, and continues to advance at a rapid pace. While the power 
of automation has been harnessed in many other industries, the biotechnology sector has lagged 
behind, largely due to the complexity of working with biological matter as well as the complexity 
and the ever-changing nature of the processes involved.1 In recent years, the automation trend has 
gained in popularity in the field of biotechnology and many companies are seeking to utilize the 
new instruments and technology available to increase efficiency as well as optimize many other 
characteristics of their processes.  
Automation has the potential to significantly increase the overall productivity of a 
biopharmaceutical company by strategically implementing it where workflow traditionally slows 
due to bottlenecks, such as in analytical departments. Yet, in addition to improving efficiency, 
automation offers the unique ability of improving reproducibility and decreasing variation by 
transferring repetitive tasks to a robot. The elimination of human error and the ability to track all 
robotic movements well suits the ultimate goal of producing a high-quality product, which is of 
utmost importance in a good manufacturing practices (GMP) compliant environment.  
 Currently, the standard for analyzing developmental drug samples is either by manually 
performed assays or on instruments dedicated to a particular assay. Therefore, we developed a 
customizable and versatile automated platform to replace a range of existing manual assays that 
test varying aspects of a monoclonal antibody drug sample.  
 In this study, we used the Hamilton Microlab STAR robot to automate two relative drug 
potency assays and one residual Chinese Hamster Ovarian (CHO) host cell protein (HCP) assay. 
For all assays, all liquid handling steps are automated and performed by the robot. In this essay, 
we demonstrate that our automated assays can achieve equal or superior accuracy and precision 
compared to their manual counterparts, have a greater maximum efficiency, and track and record 
all robotic movements performed during the assay. Furthermore, our work establishes a precedent 
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1 INTRODUCTION 
  Critical to the research and development of biopharmaceuticals is the continuous and 
periodic analysis performed to characterize a drug product throughout its developmental 
progression. A wide variety of analytical methods are employed to better understand a given 
product and can measure many aspects of a drug such as drug concentration, drug potency, 
impurity identification and concentration, as well as other physical properties of the molecule. Our 
increasing understanding of the complex nature of biopharmaceutical products as well as their 
continual growth in the therapeutic market has resulted in an ever-growing demand for 
developmental analysis.2 This increased demand has created in many analytical departments a 
bottleneck at which analysts are overwhelmed despite working at maximum efficiency. This 
subsequently results in the slowing of all developmental work for which decisions are made based 
upon the results of analytical testing. The implementation of automation offers an opportunity to 
mitigate this bottleneck with its potential to increase efficiency capable of high throughput 
analysis.  
 Laboratory automation of standard protocols is one effective method for increasing high 
throughput efficiency. However, increased efficiency is only one of the many possible benefits of 
implementing laboratory automation. The use of a robot to replace a human analyst has the benefit 
of programmed consistency and elimination of human error. Humans are prone to make mistakes, 
especially after a series of repetitive manual maneuvers from repeating similar assays. A robot is 
far less prone to mistakes. Furthermore, while a robot is not immune to errors, automation also 
comes with the added benefit that every step in an assay is recorded, a desirable feature especially 
for good manufacturing practices (GMP) compliant environments. Additionally, when 
programmed appropriately, a robot should perform the same task in the same way every time, 
giving a robot unique consistency that is difficult to achieve with a single analyst, let alone between 
multiple analysts and across departments.  
 Immunoassays are one of the most common analytical methods due to their high specificity 
and sensitivity, which allow for a reliably accurate and precise method of measurement. One of 
the most frequently used immunoassays is the Enzyme Linked Immunosorbent Assay (ELISA). 
While the ELISA is effective and reliable, its long preparation and incubation times as well as 
rigorous and repetitive liquid handling steps result in a low threshold for maximum efficiency.3 
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These characteristics, in addition to the ELISA’s generic format for a wide variety of assays, make 
the ELISA a good candidate for automation with liquid handling robots.  
 In this study, ELISA-based assays were modified from their original manual protocols and 
automated using a Hamilton Microlab STAR Liquid Handling Robot. One of the most 
foundational assays for a drug quantitatively measures its biological activity, also known as drug 
potency. In this study, two cell-based ELISAs were automated to measure the relative potency of 
monoclonal antibody drug substance, in which both drugs of interest target and bind cell surface 
ligands. Additionally, as monoclonal antibody drugs are produced in mammalian cells and 
subsequently purified, downstream processing of these samples requires the routine analysis of 
impurities from the host cell in which it was produced, including what are known as host cell 
proteins (HCPs). To this end, we modified an existing manual ELISA that measures residual host 
cell protein in drug produced in CHO cells and simultaneously developed an automated protocol 
for it. While the general procedure of an ELISA is straight forward, each assay requires a complex 
scheme for properly diluting each submitted sample.  
 We present three automated ELISA-based assays in this report, two measuring relative 
potency and one measuring residual CHO HCP. For each assay, an analyst prepares coated 
microtiter plates, reagents, and samples and loads them onto the robot, which automatically 
calculates and performs all dilutions as well as incubation and washing steps. In addition to liquid 
handling steps, all data analysis, including results and system suitability validity checks, is 
automated.  
 
2 MATERIALS AND METHODS 
2.1 Robotic System and Incorporated Instruments 
 For all automated experiments in this study, a Hamilton Microlab STAR workstation 
(Hamilton Company, Reno, Nevada) was customized and coded to perform the liquid handling 
steps of the ELISAs on 96-well microtiter plates. The workstation was outfitted with an eight-
individual channel head, a 96-channel Probe head, an iSWAP Gripper, and CO-RE Paddle 
Grippers. A peripheral microplate washer (BioTek ELx405, BioTek, Winooski, Vermont) was 
incorporated with the workstation; the robot transferred 96-well assay plates to the plate washer 
using the iSWAP gripper and communicated with the instrument to wash each plate. All samples 
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prepared automatically were finally analyzed using an Envision Microplate Reader (Perkin Elmer, 
Waltham, Massachusetts) capable of reading time-resolved fluorescence with excitation at 340 nm 
and emission at 615 nm. The workstation was customized to a particular set up for both the potency 
and HCP assays automated in this study, diagrammed in the following sections.  
 
2.2 Critical Reagents 
All critical reagents across all studies were qualified to internal company standards. Critical 
reagents for each potency assay included the respective cell line, the control, reference standard, 
and the DELFIA® Eu-N1 Anti-Human IgG (Perkin Elmer, Waltham, Massachusetts). In order to 
maintain consistency of relative potency measurements in the potency assays of this study, all 
samples (reference standard, control, and simulated potency samples) were taken from the same 
qualified drug substance lot. Simulated potency samples were dilutions of the same material with 
concentrations of 60%, 77%, 130%, and 167% relative to the control and reference standard 
concentrations.  
The residual host cell protein assay required the polyclonal capture antibody, the CHO 
HCP antigen standard, the CHO HCP antigen control, the biotinylated anti-CHO antibody, and 
DELFIA® Eu-N1 Streptavidin conjugate (Perkin Elmer, Waltham, Massachusetts). In the 
development experiments in this study, HCP antigen standard qualified material was used for the 
standard curve as well as the control and simulated samples to test for the assay’s ability to 
accurately determine HCP concentration.  
 
2.3 Cell Culture  
Each potency cell-based ELISA required a different cell type. For Potency Assay 1, P0 
HepG2 cells were thawed and cultured in DMEM supplemented with 10% FBS and 1% NEAA. 
Cells were passaged twice after reaching 80-90% confluency. After two passages, HepG2 cells 
were plated into the inner 60 wells of three Corning® PureCoat™ Amine, Black/Clear Flat Bottom 
96-well plates (VWR, US) at 150,000 cells/well in 100 µl of media. Plates were then incubated at 
37±2°C with 5±1% CO2 and greater than 85% relative humidity for 20±1 hours. After this 
incubation, plates containing HepG2 cells were allowed to equilibrate to room temperature on the 
deck of the Hamilton STAR robot.  
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In contrast to culturing cells for two passages, Potency Assay 2 used Assay Ready Banks 
(ARBs) of frozen CHO-K1 cells. While Potency Assay 1 required culturing of HepG2 cells for 
two passages, ARBs for Potency Assay 2 were frozen such that they can be directly added to assay 
plates upon thaw. Therefore, each ARB was thawed and plated into the inner 60 wells of three 
Corning 96-well poly-D-lysine coated flat bottom plates (VWR, US) at 40,000 cells/well in 100 
µl of assay media (same media as Potency Assay 1). Plates were then placed in an incubator 
overnight at 37±2°C with 5±1% CO2 and greater than 85% relative humidity for 21±5 hours. After 
incubation, plates equilibrated to room temperature while on the deck of the robot.  
 
2.4 Potency Assay Automation Protocol 
All reagents necessary for the experiment, as well as samples, dilution blocks, tips, and 
sample plates are loaded onto the deck of the Hamilton STAR liquid handling robot at the 
beginning of the procedure. The automated protocol for each potency assay can test up to 12 
samples in triplicate. In comparison to the manual method, one assay is assumed to mean 4 samples 
tested in triplicate performed in three plates with staggered row plating.  
 
Figure 1: Layout of Hamilton STAR Liquid Handling Robot for a General Potency Assay. 
The diagram displays where each item, including assay plates, deep well blocks, reagents troughs, etc., is placed on 
the deck of the robot during a general potency assay. The tip adjuster block is required for the staggered row plating 
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of the samples that is explained in Figure 2. The purple and white circles to the right indicate a rack that holds 
microcentrifuge tubes: the purple circles represent a microcentrifuge tube that is occupied by a sample, reference 
standard, or control. The gap in the middle of the deck is necessary for the arm of the robot that picks up each assay 
plate and transports it to the plate washer to have enough room to access assay plates 1-3. The waste in the top right 
of the desk is for tips used by the eight-channel head while the one in the bottom left is for tips used by the 96-channel 
head.  
 
The Hamilton software that controls the robot directs the analyst through the placement of 
each item on the deck of the robot. When prompted to place the samples on the deck of the 
instrument, the user is prompted to enter the concentration of each sample. In the first predilution 
block, the robot uses these values to calculate the appropriate volume of diluent (DMEM 
supplemented with 10% FBS and 1% NEAA) while maintaining a consistent sample volume to 
bring the reference standard, control, and samples to a uniform concentration. In the same block, 
samples are diluted two more times to a final concentration of 24 µg/ml for Potency Assay 1 and 
6 µg/ml for Potency Assay 2. In the second predilution block, all samples are transferred from the 
first block and are then serially diluted nine times 3.2-fold for Potency Assay 1 and 3-fold for 
Potency Assay 2.  
After samples have been prepared by the robot, each assay plate is washed three times in 
1x PBS (VWR, US) in the peripheral BioTek ELx405 microplate washer. Wash protocols were 
optimized to avoid disturbing the adherent cells while also efficiently washing each well; to this 
end, the first two washes are partial aspirations while the final wash removes all liquid. All wash 
steps are performed to these specifications.  
After washing, 100 µl of each prepared dilution are added to assay plates. Up to 12 samples 
can be tested at once, with 4 samples being tested in three plates in staggered row triplicates as 
shown below:  
 
Figure 2: Staggered Row Plating of Potency Samples. 
For each assay performed automatically, there is a reference standard, control, and up to four samples that are plated 
in triplicate across three different 96-well plates. The staggered row plating is designed to avoid plate effects that 
could discriminately affect one sample differently than another. Sample concentrations decrease from left to right and 
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are prepared by a serial dilution that is performed in Predilution Block 1.2, 2.2, or 3.2 (refer to Figure 1) depending 
on its placement in the automated assay.  
 
Samples are incubated on the deck of the robot at room temperature, as well as all further 
incubations, for 40 ±10 minutes (Potency Assay 1) and 50 ±10 minutes (Potency Assay 2). When 
the incubation is finished, plates are washed three times again in 1x PBS and incubated again in 
100 µl/well of 65 ng/ml DELFIA Eu-N1anti-human IgG for 60 ±10 minutes. Plates were washed 
again and then incubated with 100 µl/well of DELFIA® Enhancement Solution for 45 minutes, 
after which the plates are manually removed from the deck of the Hamilton robot and read by an 
EnVision Microplate Reader using time-resolved fluorescence with 340 nm excitation and 615 nm 
emission.  
 
Figure 3: General Potency Assay Procedure at the Molecular Level.  
The diagram shows a sketch a of what happens at the molecular level during the ELISA procedure. First, 
cells are coated onto the surface of each well (cells are represented by light blue oval with dark blue 
circumference). Each cell displays a ligand (purple rectangle) that the drug sample binds. The mAb drug 
is then bound on its Fc region by a secondary immunoglobulin G antibody that is conjugated to Perkin 
Elmer’s DELFIA Europium. Upon incubation with DELFIA Enhancement solution, the Europium is 
released and can be activated with absorbance light at 340 nm and emits light at 615 nm.  
 
The figure above presents the general format by which both potency assays operate at the 
molecular level. Each incubation in the assay represents a different molecule binding the scaffold 
pictured above, in which the final step involves activating the DELFIA Europium signal.  
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2.5 Residual CHO HCP Automation Protocol 
As with the potency assays, all reagents, samples, dilution blocks, tips, sample plates, and 
other required equipment are loaded at the start of the automated CHO HCP assay as directed by 
the program. The assay can accommodate up to 36 samples on a total of nine assay microplates.  
 
Figure 4: Hamilton Microlab STAR Deck Layout for the Residual CHO Host Cell Protein Assay.  
The diagram shows where each item involved in the automated ELISA procedure to measure residual CHO HCP sits 
on the desk of the Hamilton STAR. The two microcentrifuge tubes present represent the stock control and the stock 
spike solutions.  
 
96-well EIA/RIA clear flat bottom polystyrene high binding microplates (Corning) are 
coated with 100 µl/well of an in-house polyclonal capture antibody at 4 µg/ml in 1x PBS. Plates 
are incubated overnight at 2-8°C for at least 16 hours (up to 7 days). After overnight incubation, 
the plates are allowed to equilibrate to room temperature for 30 minutes on the deck of the 
Hamilton STAR. After the plates have come to equilibrium, the robot transfers each plate 
consecutively to the BioTek plate washer where each plate is washed three times in 300 µl/well of 
1x PBS/0.05% Tween-20 wash buffer, which is used for all wash steps throughout the assay. After 
washing, the robot dispenses 250 µl/well of 1% BSA 1xPBS/0.1% Tween-20 blocking 
buffer/assay diluent and incubates on the deck of the robot for 2 hours. During this time, dilutions 
of standard curve, control, samples, and sample spikes are performed automatically by the robot. 
For up to 36 samples of varying impurity concentrations, the Hamilton STAR can efficiently 
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perform all necessary dilutions during the two-hour incubation, which allows the program to make 
use of Hamilton’s parallel processing, making this assay highly efficient.  
During the blocking incubation, the robot first prepares the standard curve and spike 
solution using stock CHO HCP antigen, the positive control from qualified CHO HCP positive 
control, and the negative control from assay buffer in a 2 ml deep 96-well block.  
The robot then performs dilutions of all samples and sample spikes according to data 
regarding expected impurity amount that is input by the analyst. Using a preprogrammed hitpick 
file in Microsoft Excel, the analyst inputs the sample identification number and its corresponding 
dilution factor ranging from 1:2 to 1:2000 that is estimated based on its expected impurity 
concentration. The hitpick file generates three .CSV worklists that the robot uses to calculate and 
perform each sample dilution.  
 Samples are loaded by the analyst into the top half of a 2 ml deep 96-well block and the 
robot performs the first dilution into the bottom half of the block and the second dilution into the 
top half of a second block. After each sample is at the appropriate concentration in the top half of 
the second block, the robot uses that material and the previously prepared spike material to 
generate the up to 36 spiked samples in the bottom half of the second block. Spiked samples are 
spiked with 250 ng/ml antigen by a 90 vol% sample and 10 vol% spiking material (2500 ng/ml).  
 
Figure 5: Dilution Scheme for up to 36 Host Cell Protein Samples.  
At the start of the assay, the analyst dispenses up to 36 samples in the top half of Block 1, indicated by positions 
1A-36A. From this, the robot performs two dilutions to achieve the final sample concentration, starting from the 
top of Block 1 to the bottom, and then a second dilution from the bottom of Block 1 to the top of Block 2. Then, 
slightly less than the 1 mL of liquid in each sample in the top of Block 2 (1C-36C) is transferred to the bottom of 
Block 2 for the spiked samples (1°-36°).  
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The contents of block 2 above then becomes the starting material for the series of three 1:2 whole 
plate dilutions performed using the robot’s 96-probe head such that each sample, including spikes, 
is represented by a 1:1, 1:2, 1:4, and 1:8 dilution.  
After the two-hour blocking step, the plates are washed three times and the robot then adds 
the standard curve, samples, sample spikes, and controls in the following pattern:  
 
Figure 6: Residual CHO Host Cell Protein Assay Plate Layout.  
In each assay plate, the standard curve ranges from 4500 ng/ml known HCP to 2 
ng/ml and is plated in duplicate. Each sample is represented on the plate in a 
standard and spiked solution in rows A-H with a series of 1:2 dilutions in 
columns 3&4, 5&6, 7&8, and 9&10. Positive and negative controls are located 
in columns 11 and 12. 
 
After the robot is finished dispensing into the first plate (of maximum nine), a timer of 80 
minutes is started while the robot finishes the remaining plates. Including the time it takes the robot 
to plate each sample as well as the time it takes to wash each plate, any given assay plate incubates 
between 40 and 80 minutes. This range of incubation time was confirmed using a design of 
experiment study (see Appendix).  
The assay plates are washed after the sample incubation and are incubated for 60 minutes 
in 100 µl/well of in-house biotinylated anti-CHO antibody at 2 µg/ml in assay diluent. Plates are 
washed three times again, and subsequently incubated in 65 ng/ml of Streptavidin conjugated 
Europium in assay diluent for 60 minutes. Plates are washed three times, and finally incubated in 
DELFIA Enhancement Solution for 45 minutes on the deck on the deck of robot. At the end of this 
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incubation, all nine plates are analyzed on a Perkin Elmer EnVision Microplate Reader using time-
resolved fluorescence with 340 nm excitation and 615 nm emission.  
 
Figure 7: CHO Host Cell Protein Assay at the Molecular Level.  
Overnight, a capture polyclonal antibody (pAb) is coated onto the surface of a 96-well plate. After blocking with BSA, 
the sample is then incubated (represented as purple oval) and is captured by the coating pAb. After the sample, the 
assay is then incubated with a biotinylated anti-HCP antibody (represented by the green antibody with blue circle). 
The Streptavidin conjugated Europium then binds the biotinylated antibody and is activated by the same Enhancement 
method as in the potency assays.  
 
The above figure displays the molecular level binding steps that happen during each incubation 
presented above. Because the assay uses the same DELFIA Europium signal as the potency assays, 
it has a similar mechanism in which each incubation represents a new molecule adding to the 
scaffold, the final step of which activates the Europium signal.  
 
2.6 Data Analysis and System Suitability 
All data analysis is automated using the SoftMax Pro data analytic software (Molecular 
Devices, San Jose, California) for both potency assays and for the CHO HCP assay. Each assay 
has a dedicated SoftMax Pro template that only requires the manual input of raw data which the 
template then processes and automatically presents the final results.  
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Relative potency is calculated by first generating four-parameter logistic regression plots 
of each reference standard, control, and sample calculated from a plot of relative fluorescence units 




, + 𝐷										𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	1 
where the coefficient A is the minimum response (Y value) at the lower asymptote and D is the 
maximum response at the upper asymptote. The coefficient C EC50 is the concentration (value 
from the X-axis) that results in 50% of the maximal response. The coefficient B is the slope factor 
that describes how rapidly the curve transitions between the upper and lower asymptotes in the 
center of the curve. After assessing similarity, a constrained 4PL curve fit is performed and relative 
potency (%RP) of the drug samples is calculated by dividing the EC50 of the reference standard by 
the EC50 of each sample and multiplying by 100%. 
In order for each potency assay to pass, the assay control must be parallel to the reference 
standard and must generate a relative potency between 75% and 133%; otherwise, all samples 
associated with that control fail and must be repeated. Individual samples must also be parallel to 
the reference standard to pass.  
In order to be considered parallel to the reference standard, the following criteria must be 
met:  
Table 1: System Suitability for Potency Assays 
Reference Range Parallelism Criteria 
Lower bound, effective asymptote (D-A) ≥ 0.85 
Upper bound, effective asymptote (D-A) ≤ 1.15 
Lower bound, upper asymptote (D) ≥ 0.85 
Upper bound, upper asymptote (D) ≤ 1.15 
Slope Ratio (lower bound) ≥ 0.7 
Slope Ratio (upper bound) ≤ 1.3 
R-square ≥ 0.970 
 
 The host cell protein assay also uses a four-parameter logistic regression to calculate the 
measured impurity in each given sample. Using SoftMax Pro, a graph of relative fluorescence units 
versus concentration is plotted for the standard curve, which ranges in known concentrations from 
4500 to 2 ng/ml. Impurity values for all samples are then calculated by interpolating the x value 
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concentration. Accompanying each sample is a spiked sample with a spike concentration of 250 
ng/ml. The spike percent calculation is:  
 




∗ 100 = 𝑆𝑝𝑖𝑘𝑒	𝑃𝑒𝑟𝑐𝑒𝑛𝑡				𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	2 
 
3 RESULTS 
The ultimate goal of the work presented in this thesis is to demonstrate the significant 
advantage that the collective sum of benefits of automation has to offer and to present a platform 
by which other similar assays may be more easily translated into an automated environment. Here, 
we present the results of six months of development work that produced the full automation of 
three assays: two relative potency assays and one residual host cell protein assay. All assays are 
automated using the same Hamilton Microlab STAR Liquid Handling Robot, which is customized 
for each assay. Regardless of the assay, each ELISA is automated from start to finish, as well as 
all data analysis.   
 
Figure 8: Diagram of Overall General Automated Bioassay.  
For each automated assay presented in this essay, the analyst must first prepare all reagents, assay plates, and samples 
necessary for the assay, as well as collect all information required to give to the robot, such as desired dilution or 
sample concentration. These are all placed onto the deck of the robot in locations that are dictated by each assay’s 
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corresponding program. Once the assay is begun, the assay is completely hands-off until all liquid handling steps are 
finished. Then, the analyst moves all assay plates to a Perkin Elmer EnVision microplate reader that reads the 
fluorescence. From this, the analyst copies the raw data into a pre-programmed SoftMax Pro template that 
automatically analyzes and reports the final results. All images come from the websites of the respective companies 
detailed in Materials and Methods, or from open source data.  
 
The above diagram demonstrates the typical procedure for performing any of the assays. In order 
to operate, the analyst must prepare all reagents, assay plates, and samples ahead of time, as well 
as any data that is necessary for the robot to complete the assay. Once all materials are on the robot, 
all steps are automated until the end of the ELISA liquid handling, at which point the analyst 
removes all assay plates and measures them using a preconfigured program on a Perkin Elmer 
EnVision Fluorescence Microplate Reader. The analyst then copies the data into a programmed 
template that then automatically analyzes and reports all results.  
 
3.1 Relative Potency Assays 
In this study, we automated two relative potency assays that measure the biological activity 
of monoclonal antibody drugs. Potency Assay 1 measures the relative potency of Drug 1 and was 
developed first while Potency Assay 2 measures the relative potency of Drug 2 and was developed 
by modifying Potency Assay 1. Here we present data demonstrating how both assays are 
statistically similar to their manual counterparts. In order to evaluate each assay, we tested them 
for accuracy, precision, intermediate precision, linearity, and agreement. Additionally, we report 
other specifications of the automated assays, including total run time, analyst time, and maximum 
throughput.  
 To assess the validity of the above parameters, both potency assays tested four simulated 
potency samples: 60%, 77%, 130%, and 167% as well as a 100% control. All samples were tested 
on the new automated method as well as the qualified manual method for reference. Manually, all 
samples were tested a total of six times across two different analysts; on the automated platform, 
all samples were also tested six times across two separate runs on the same robot.  
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Figure 9: Accuracy of Simulated Potency Samples.  
Accuracy is calculated by dividing the geometric mean of the observed values by the expected value and multiply by 
100%. (A) Potency Assay 1 (B) Potency Assay 2.  
 
 The above data in Figure 9 represents the accuracy of each simulated sample for both the 
manual and automated versions of both relative potency assays. Across all assays, both manual 
and automated, the maximum range of accuracy does not extend beyond 92% – 111.  
 Precision of each assay was evaluated for intra-assay precision as well as overall assay 
precision.  
 
Figure 10: Precision of Simulated Potency Samples.  
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 (A) Intermediate Precision per Level Potency Assay 1 (B) Intermediate Precision per Level Potency Assay 2 (C) 
Overall Intermediate Precision Assay 1 (D) Overall Intermediate Precision Assay 2.  
 
Figures 10 A-D demonstrate the precision of both potency assays. Figures 10A and 10B represent 
the intra-assay precision, or repeatability, of each simulated potency sample and are calculated by 
determining the % geometric coefficient of variation across all six tests for all simulated samples, 
both manual and automated. Individual sample % geometric CV was calculated by the following 
equation: 
 
%	𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐	𝐶𝑉 = expOP𝑀𝑒𝑎𝑛	𝑆𝑞𝑢𝑎𝑟𝑒𝑑	𝐸𝑟𝑟𝑜𝑟R − 1 ∗ 100%			𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	3 
 
Overall intermediate precision was calculated similarly by using the arithmetic mean of the total 
five mean squared errors for each simulated sample. For Potency Assay 1, the automated assay 
has consistently smaller CVs than that of the manual method, while Potency Assay 2 more closely 
agrees with its manual counterpart (bar the 77% sample that is higher). Additionally, Figures 10C 
and 10D demonstrate the similarity between the overall precision of the manual and automated 
assays. Furthermore, across all assays, CVs did not exceed 10%, demonstrating that each 
automated assay maintains the overall precision of their manual counterparts.  
 To further assess the overall quality of the automated assays developed, we calculated the 
linearity of the simulated samples, ranging from 60% to 167%.  
 
Figure 11: Linearity of Simulated Samples. 
The geometric mean of all simulated samples within each assay is plotted as the observed potency against its 
corresponding expected potency. (A) Potency Assay 1 (B) Potency Assay 2.  
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 As seen in the above figure, all simulated samples across all assays demonstrate a strong 
linear relationship throughout the tested range, with all R2 values well above 0.95. Furthermore, 
each automated assay has significantly similar R2 values to its manual counterpart, demonstrating 
that our automated assay maintains the linear integrity of the existing assays. This well-preserved 
linearity demonstrates that the automated methods developed in this study can reliably measure a 
given sample for its relative potency within this region of values.  
 Finally, the automated methods were tested for agreement with the manual methods with 
which we aim to replace them. While the linear relationship presented above demonstrates a strong 
correlation between the manual and automated methods, it does not account for agreement between 
them. Commonly used for assessing the agreement between two methods that measure the same 
parameter, the Bland-Altman plot in Figure 12 below represents the ratio of means of manual 
versus automated methods (mean observed manual potency / mean observed automated potency).  
The mean ratios for each assay, 0.981 and 0.994, respectively, demonstrate that the two methods 
on average return near identical results for a given sample. All averaged simulated samples fall 
within two standard deviations and the standard error for each sample also predominantly remains 
within two standard deviations, demonstrating the agreement between the two assays.  
 The distribution trend between the two assays is also worth noting. For four out of the five 
simulated samples, the ratios of means are skewed in the same direction across both assays. For 
example, the reported ratio for the 60% simulated sample is slightly over 1.0 while it is slightly 
under that for the 77% sample across both assays, indicating that the automated method produces 
lower and higher results for each sample, respectively. While the values of each sample are not 
significant and seem to be distributed normally, the striking resemblance in the trends between the 
two assays suggests that there is potentially a noticeable difference between the automated 
platform and the manual.  
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Figure 12: Ratio of Means of Manual vs. Automated Methods.  
The solid black line represents the average of all samples from the manual assays divided by that of the automated 
assays. Each data point represents the ratio of the mean of each simulated manual sample divided by each automated 
sample, including bars for standard error. The dashed red lines represent two times the standard deviation. (A) Potency 
Assay 1: The mean is 0.981 and two times the standard deviation is 0.14. (B) Potency Assay 2: The mean is 0.994 and 
two times the standard deviation is 0.05.4,5 
 
 For both automated assays, each program can be completed in under 5 hours. Excluding 
the cell culture preparation the day prior which should take no longer than 30 minutes, analyst time 
the day of the assay does not exceed 30 minutes, reducing total analyst time to under an hour over 
two days. Each assay can accommodate a maximum of 12 samples. In comparison, an analyst can 
comfortably do only 4 samples at a time, which would take up the majority of the analyst’s day.  
 
3.2 Residual CHO Host Cell Protein Assay 
The third assay presented in this essay is an assay to measure residual CHO host cell protein 
in development drug samples that, in contrast to the previous assays that were automated versions 
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of their manual counterparts, was developed and automated simultaneously. The assay was 
developed from its original ELISA version that used the traditional horseradish peroxidase (HRP) 
enzyme. The HRP enzyme catalyzes the oxidation of numerous substrates that, when oxidized, 
change color. Thus, it has been used in a conjugated form very effectively as a method of detection 
in ELISAs using relatively inexpensive spectrophotometer instruments. However, its rapid 
reaction rates as well as its relative instability make it an undesirable candidate for high-throughput 
automation. Therefore, in this study, we adapted the existing manual CHO host cell protein ELISA 
to use Perkin Elmer’s DELFIA Europium, with which we have previously demonstrated success 
in automation, in lieu of the HRP enzyme and its corresponding substrate. Simultaneously, we 
developed an automated method using the Hamilton Microlab STAR that can accommodate up to 
36 samples. At its maximum capacity, the assay takes six and a half hours to run on the robot with 
a total manual time of 45 minutes, bringing the assay to a total of just over seven hours, easily 
achievable within the 8-hour workday.  
In addition to increased stability and therefore its availability for use in an automated 
environment, the use of Perkin Elmer’s fluorescent Europium chelate has other significant 
advantages.  
 
Figure 13: Dynamic Range of HCP Assays.  
DEFLIA Europium Chelate vs. Horseradish Peroxidase reaction with ABTS. By using Europium rather than the HRP 
enzyme, our assay can accommodate a dynamic range 22.5 times as large as the HRP’s range.  
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The above figure demonstrates the difference in standard curve range between the two assays: the 
use of Europium increases the dynamic range of the assay by more than 22-fold, dramatically 
increasing the range of impurity concentrations that the assay can accurately detect. Because the 
impurity concentration is unknown before the assay is run, having a wider dynamic range results 
in a greater chance that the impurity concentration can be identified, decreasing the number of 
samples that need to be retested. In addition to increased range, the Europium allows for a more 
linear standard curve leading to a more overall proportional assay.  
 
Figure 14: Linearity of Standard Curves.  
Observed and expected values of host cell protein are plotted against each other for each value of the standard curve 
in (A) the HRP and ABTS substrate assay and in (B) the Europium assay.  
 
The data above were taken from two independent runs of both assays in which the standard curves 
of known host cell protein concentration of both assays were plated in triplicate and duplicate for 
the HRP and Europium assays, respectively, and each value of the curves was then processed to 
determine their recovered values for HCP impurity. The graphs above show the observed values 
of host cell protein concentration in each point of both standard curves that each assay recovered 
in comparison to the expected values calculated from dilutions of known concentrations of stock 
host cell protein. The Europium ELISA demonstrates improved linearity as well as a slope closer 
to unity than the HRP assay. The increased linearity shows that the Europium assay is more 
consistent throughout its range and its slope of 1.03 demonstrates its overall improved accuracy 
over the HRP assay, with a slope of 0.90.  
 To further assess the performance of the newly developed CHO residual host cell protein 
assay, we tested each point of the standard curve as simulated samples plated in triplicate across 
four different manual trials. The data are collected in the table below:  
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% Accuracy %CV % Standard 
Error 
4500 5423.2 120.5% 17.9% 11% 
1500 1312.8 87.5% 12.7% 6% 
500 492.5 98.5% 17.3% 9% 
166.7 163.0 97.8% 22.1% 11% 
55.6 49.7 89.5% 13.4% 6% 
18.5 18.1 97.8% 14.1% 7% 
6.2 7.3 117.6% 5.2% 3% 
2.1 4.5 218.4% 30.0% 33% 
 
The above data were analyzed for accuracy, precision, and linearity. The figure below shows the 
accuracy and precision of the assay according to each sample within the standard curve.  
 
Figure 15: Accuracy and Precision of the Manual Europium HCP Assay.  
(A) Accuracy (B) Precision, represented by the %CV of each simulated sample.  
 
The above data show that the majority of the concentrations in the standard curve can be recovered 
with both good accuracy and precision. In between 6 ng/ml and 1500 ng/ml, the assay can 
accurately report the simulated concentrations within 17% above and 13% below the target with 
an average % CV of 14.1%, which falls under the 15% typically used as a benchmark. Furthermore, 
the assay demonstrates strong linearity.  
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Figure 16: Linearity of Manual Europium HCP Assay.  
 (A) The observed versus expected HCP values are plotted without modification compared to (B) The natural log is 
taken of each individual value and graphed separately due to the exponential nature of the standard curve.  
 
Figures 16A and 16B above demonstrate the assay’s linearity across all simulated HCP samples 
of the standard curve. The data were analyzed for linearity by comparing the observed HCP found 
by the assay to the expected concentration without alteration as well as modifying the data set by 
taking the natural logarithm due to the standard curve’s exponential nature. Both methods report 
an R2 value above 0.99 as well as a slope close to unity. The linear nature of the assay we have 
developed in this study demonstrates its ability to recover proportional results throughout the range 
of the standard curve.  
 While the assay recovers simulated samples in the middle of its range well, it is more 
variable at the topmost and bottommost ends of the range. This is normal for an assay of this 
nature; however, in order to better understand our assay, we conducted a study to evaluate the 
upper and lower limits of quantification for this assay. Therefore, we performed a series of 
experiments that tested simulated samples at the lower and upper end of the curve. The experiments 
tested nine simulated HCP samples three separate times in four 1:2 dilutions and in duplicate using 
the automated method we developed on the Hamilton Microlab STAR.  
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Figure 17: Accuracy and Precision of Upper and Lower Limits of Automated HCP Europium Assay. 
 (A) Accuracy of simulated samples from upper (4500, 4250, and 4000 ng/ml HCP) and lower limits (12, 10, 8, … 2 
ng/ml HCP) of the standard curve. (B) Precision of each simulated sample reported as %CV.  
 
The above figure shows the accuracy and precision of all nine simulated samples across all trials: 
the first three samples that tested the upper limit of quantification demonstrate both accuracy and 
precision. In comparison to Figure 15 that showed insufficient accuracy and precision for the 4500 
ng/ml simulated host cell protein sample, these data demonstrate otherwise, most probably because 
these simulated samples are tested in a series of dilutions. The series of 1:2 dilutions is standard 
on the assay in order to achieve a greater chance of obtaining a result within the working range 
outlined in Figure 13. The following six simulated samples that tested the lower region see a 
decrease in accuracy as the series of dilutions begin to negatively affect the assay results due to 
the lower limit of quantification. The data presented above suggest that 6 ng/ml is the lower limit 
of quantification, yet further work is required to statistically prove this.  
 The series of 1:2 dilutions as well as the automation made significant improvements to the 
data presented; to better understand the performance of the dilutions themselves, we analyzed the 
data from the three simulated samples that tested the upper limit of quantification (because the 
lower simulated samples’ dilutions result in concentrations below the level of quantification). The 
three simulated samples, 4500, 4250, and 4000 ng/ml HCP, were analyzed by their individual 




Figure 18: Normalized Linearity of 1:2 Dilutions.  
The data plotted above shows the linearity of the 1:2 dilutions (1:2, 1:4, and 1:8, as well as the original 1:1) for the 
three samples that tested the upper limit of the standard curve: 4500, 4250, and 4000 ng/ml. Lower samples were not 
used since the lowest dilutions will not fall within the lower limit of the assay. Since concentrations for each sample 
come from different initial simulated samples, values were normalized to the percentage that each dilution should 
represent (i.e., 1:1 should be 100%, 1:2 50%, etc.).  
 
The linearity observed in the data in Figure 18 (R2 is 0.997) demonstrates that the robot dilutes all 
samples properly and the assay can accurately return values of all dilutions that still fall within the 
range of the quantification. The slope slightly below 1.0 in the above figure is most likely the result 
of the concentrations of the first dilution (1:1) being near to the upper limit of the assay.  
 The final aspect of our newly developed host cell protein assay that we tested evaluated 
the assay’s ability to recover a simulated host cell protein sample in the presence of known 
impurities likely to be found in typical samples, including CHO Protein A, Insulin, and DNA. We 
performed experiments in which a known concentration of CHO HCP antigen was tested by our 
assay in the presence of a known concentration of the above impurities, data for which is presented 
below on both the manual and automated methods.  
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Figure 19: Accuracy and Precision of Simulated HCP Samples with Additional CHO Impurities.  
Each simulated sample was tested three times on each method, manual and automated. All samples contain 250 ng/ml 
of HCP. HCP + Pro A samples contain 30 ng/ml of residual Protein A, HCP + Insulin samples contain 50 µIU/ml of 
residual Insulin, and HCP + DNA samples contain 30 ng/ml of residual CHO DNA. (A) Accuracy of all samples and 
(B) Precision of all samples represented as %CV.  
 
The data above suggest that the newly developed assay using Europium is unaffected by the 
presence of other residual impurities. Accuracy values for both the manual and automated assays 
maintain their consistency across the different impurity samples. There is, however, a significant 
difference in accuracy between the manual and automated versions of the assay. While the manual 
assay is more consistently accurate than the automated assay, the automated assay is overall more 
precise. One way to rationalize this result is that the robot, while able to pipette very precisely, is 
programmed in a manner that resulted in an overshoot in recovering known sample concentrations. 
While these data demonstrate that both assays can function effectively in the presence of the most 
common impurities external to the assay objective, more experiments should be performed to test 
the robustness of the automated method’s dilution accuracy.  
 
4 DISCUSSION AND FUTURE DIRECTIONS 
The automated assays presented in this thesis have significant advantages over their manual 
counterparts, and even more potential advantages that have yet to be explored. Our assays have 
completely automated ELISA procedures as well as automated preparatory dilutions and data 
analysis. Automation of sample dilutions is in particular important for the residual host cell protein 
assay, in which the dilutions can vary between 2 and 2000-fold from sample to sample and run to 
run with no predictable pattern. The automation of both the dilutions and their corresponding 
calculations affords the analyst not only the convenience of not having to manually perform liquid 
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handling tasks but also completes them dramatically faster than an analyst could manually. At the 
manual rate, an analyst could not calculate and perform all dilutions for an equivalent maximum 
capacity compared to the automated protocol while also completing the assay within the workday, 
making the automation of sample dilutions as well as their calculations one of the best advantages 
that the automated protocol offers. Furthermore, we have demonstrated that automated assays can 
achieve equal or superior accuracy and precision over their manual counterparts. Additionally, 
every assay in this essay automatically generates a file that records every movement of the robot, 
providing more accountability than with a manual assay.  
In addition to the successes outlined above, there are a series of steps that can dramatically 
improve these bioassays with more development. One addition that we explored but did not finish 
during this study is the addition of a barcode to each assay plate that can be read by both the liquid 
handling robot as well as the microplate reader and then subsequently be fed into the analytical 
software. Because each sample is already coded within an existing system and the liquid handling 
robot comes equipped with a barcode reader, a barcode on each plate would allow for complete 
automation of the assay, including data analysis, from the point that the samples enter the robot to 
the final sample result.  
Additionally, a step missing from the assays developed here that significantly limits their 
operation is the robotic transfer of plates to the microplate reader, which currently happens 
manually. The automation of this step is not complex and involves placing a dedicated microplate 
reader next to the liquid handling robot and connecting the two with a communication pathway. 
Theoretically, the robot could use its already existing arm to place each plate on the reader that 
would then use the barcode mentioned above to direct the microplate reader to operate the 
appropriate program with which to read the plate and then subsequently open the correct analytical 
software to process and analyze the raw data. These two additions are critical to automating the 
bioassays from the beginning of the assay to the final result. This is not only advantageous for all 
the reasons listed throughout this essay, but it would also enable the assay to be operated twice as 
often: once that begins and ends during business hours and a second that starts at the end of 
business hours and finishes after they conclude. These two additions could effectively double the 
efficiency of the assays presented in this essay.  
While each assay presented here is a success in and of itself, the developmental work done 
to create them establishes successful methods for overcoming many of the hurdles one faces when 
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replacing manual assays with automated assays. A series of environmental differences between a 
manual and automated setting that dictate what can and cannot be done during an automated assay 
were tested such that automation adaptation could be feasible. These include differences such as 
protecting the assays from light, plate wash protocols, and the use of plate shakers. While all of 
the above factors are easily controlled by a human, an automated robot cannot adjust for these 
without the proper intelligence and mechanical equipment. For example, all manual plate washing 
protocols call for using the BioTek plate washer followed by tapping the 96-well microtiter plate 
onto non-shredding paper towels, which is not feasible for a robot to do. By developing robust 
methods for circumventing these hurdles, we have established a precedent that will streamline 
further automation.  
In addition to achieving complete automation, there are many aspects of the assays 
presented here whose altering would improve their overall robustness. For example, while the host 
cell protein assay can accommodate up to 36 samples, the assay could be modified to instruct the 
user to only supply the robot with the amount of reagents needed for the particular number of 
samples it needs to run. This would involve putting the assay through a battery of tests to determine 
exactly how much is needed for each condition.  
The power of automation is easily seen from the work presented in this essay, as well as 
from the advances it has produced across different industries. However, there are problems that 
still exist in the assays developed here, as well as inherent weaknesses of automation that are more 
challenging to overcome. For example, the Hamilton robot is less skilled at aspirating liquid from 
very small volumes. The Hamilton Microlab STAR is equipped with advanced technologies that 
use conductance to detect liquid surface levels, but depending on the amount of liquid, the vessel 
shape and size, and the viscosity of the liquid, it can be more or less effective. In contrast, a trained 
human analyst with a microcentrifuge tube with only a few microliters of liquid can easily observe 
the liquid level and almost always pipette correctly. This artifact of the robot results in its 
overconsumption of reagents, which are especially expensive when using Perkin Elmer’s DELFIA 
reagents that are used throughout this study. In addition to purchased reagents, critical reagents 
that are made and qualified in-house are significantly more precious and their over-consumption 
presents a potential problem due to the difficulty of remaking and requalifying a new batch of 
critical reagent, which would affect many departments throughout the business. Another 
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consequence of the robot’s limitation is that it will occasionally pipette air bubbles and not report 
an error, completing the assay incorrectly and yielding inaccurate or incomprehensible results.  
Furthermore, the assays developed here suffer from non-recoverable robotic errors. If an 
error occurs, such as a pipette not being able to secure a pipette tip correctly or a 
miscommunication between the robot and the plate washer, both of which are not uncommon, the 
robot has a limited ability to resolve the issue on its own, requiring manual intervention. Moreover, 
in order to even have options to resolve such issues, every scenario that could result in an error 
must be predicted in order for the robot to be intelligent enough to know what to do in the event 
of an error.  However, even manual intervention is often not sufficient to resolve the issue. Because 
the assays cannot be started from midway through the experiment without altering the robot’s 
code, the assay becomes unrecoverable, losing both time, reagents, and samples.  
5 CONCLUSION 
The work presented in this thesis highlights the benefits, as well as the potential 
weaknesses, of integrating customizable automated liquid handling into routine analytics in 
biopharmaceuticals. Yet, regardless of its potential pitfalls, the ultimate reality is that in order for 
biotechnology companies to remain competitive and to maintain efficiency with an evergrowing 
analytical demand, the incorporation of automation is necessary. The work presented here 
demonstrates significant strides for the immediate yet limited incorporation of automation into the 
everyday lives of analytical sciences. We have yet to see the full capability of customizable liquid 
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7 APPENDIX: SUPPLEMENTAL DATA 
The data presented in the body of this thesis represents the evaluation of months of 
development work into the three corresponding assays, not to mention extensive troubleshooting. 
The following section supplies some of the most significant development studies in addition to 
exact numbers represented in results figures for reference.  
 
Table 3: Drug Potency Assay 1 Data 
Simulated Potency Sample 60% 77% 100% 130% 167% 
Geometric Mean Manual 65% 78% 103% 133% 162% 
Geometric Mean 
Automation 
61% 85% 107% 128% 176% 
% Accuracy Manual 109% 101% 103% 102% 97% 
% Accuracy Automation 101% 111% 107% 98% 105% 
Repeatability (%GCV) 
Manual 
9.1% 9.3% 6.7% 3.5% 7.2% 
Repeatability (%GCV) 
Automation 
7.3% 4.3% 4.0% 1.3% 7.5% 
Ratio of Means 1.073 0.914 0.962 1.037 0.922 
 
Table 4: Drug Potency Assay 2 Data 
Simulated Potency Sample 60% 77% 100% 130% 167% 
Geometric Mean Manual 57% 76% 105% 130% 179% 
Geometric Mean 
Automation 55% 80% 106% 129% 180% 
% Accuracy Manual 94% 99% 105% 100% 107% 
% Accuracy Automation 92% 103% 106% 99% 108% 
Repeatability (%GCV) 
Manual 3.0% 2.8% 4.4% 4.9% 6.2% 
Repeatability (%GCV) 
Automation 4.4% 6.7% 4.6% 3.7% 4.3% 
Ratio of Means 1.019 0.954 0.991 1.009 0.998 
 
The above tables are the exact numbers for Figures 9-12 
 Perhaps the most important study performed for the development of the work presented in 
this essay is the establishment of a new residual HCP assay. While the drug potency assays were 
automated versions of existing manual assays, the residual HCP assay was a newly designed 
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ELISA. With a series of components to work with, we completed a design of experiment in order 
to best determine the operating conditions of many of the components in the assay.  
 
Figure 20: DOE for Establishing a Residual CHO HCP Assay using DELFIA Europium.  
 
The above data shows the results from our DOE that tested the following assay variables: coating 
polyclonal antibody concentration, biotinylated antibody concentration, sample incubation time, 
and biotinylated antibody incubation time. The data presented above comes from a total of 52 
combinations of the previously listed variables at different values in between what is shown on the 
figure’s x-axis. This experiment was critical in our determination of the final variables that are 
explicitly described in the Materials and Methods section. One of the most critical components of 
the above study was the sample incubation time. Because of the way the automated protocol plated 
samples into and washed each of the nine assay plates, it was critical that the sample incubation 
time not affect the final sample results between 40 and 80 minutes, which is well demonstrated in 
the desirability graph for sample time incubation in Figure 20.  
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